Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 488-496

  Wang, Jian Gang ^a   Zheng, Xing Xing ^a   Zeng, Guang Yao ^a   Zhou, Ying Jun ^a   Yuan, Hong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

AKT; Apoptosis; ERK; FOXO3a; Hepatocellular carcinoma; Purified vitexin compound 1

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CASPASE 3; CASPASE 8; CASPASE 9; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROPIDIUM IODIDE; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; VITEXIN; VITEXIN COMPOUND 1;

AGAR GEL ELECTROPHORESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DETERMINATION; DNA FRAGMENTATION; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; STAINING; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

APIGENIN; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA FRAGMENTATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; FORKHEAD TRANSCRIPTION FACTORS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA INTERFERENCE; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTIONAL ACTIVATION;

EID: 84891932499     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2855     Document Type: Article

References (45)

1. Zhu AX: Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol 39: 493-502, 2012.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Padma S, Martinie JB and Iannitti DA: Liver tumor ablation: percutaneous and open approaches. J Surg Oncol 100: 619-634, 2009.
4. Ichida T, Van Thiel DH and Hassanein T: The medical management of hepatocellular carcinoma (HCC) in Japan: a review with implications for HCC seen in the west. Hepatogastroenterology 43: 1575-1583, 1996.
5. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
6. Llovet JM, Real MI, Montaña X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739, 2002.
7. Choo CY, Sulong NY, Man F and Wong TW: Vitexin and isovitexin from the leaves of Ficus deltoidea with in-vivo α-glucosidase inhibition. J Ethnopharmacol 142: 776-781, 2012.
8. Knipping K, Garssen J and van't Land B: An evaluation of the inhibitory effects against rotavirus infection of edible plant extracts. Virol J 9: 137, 2012.
9. 4-induced damage in rat. BMC Complement Altern Med 11: 48, 2011.
10. Lee CY, Chien YS, Chiu TH, et al: Apoptosis triggered by vitexin in U937 human leukemia cells via a mitochondrial signaling pathway. Oncol Rep 28: 1883-1888, 2012.
11. Papi A, Farabegoli F, Iori R, et al: Vitexin-2-O-xyloside, raphasatin and (-)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells. Food Chem 138: 1521-1530, 2013.
12. Xin H, Kong Y, Wang Y, et al: Lignans extracted from Vitex negundo possess cytotoxic activity by G2/M phase cell cycle arrest and apoptosis induction. Phytomedicine 20: 640-647, 2013.
13. Zhou Y, Liu YE, Cao J, et al: Vitexins, nature-derived lignan compounds, induce apoptosis and suppress tumor growth. Clin Cancer Res 15: 5161-5169, 2009.
14. Tan Z, Zhang Y, Deng J, Zeng G and Zhang Y: Purified vitexin compound 1 suppresses tumor growth and induces cell apoptosis in a mouse model of human choriocarcinoma. Int J Gynecol Cancer 22: 360-366, 2012.
15. McCubrey JA, Steelman LS, Chappell WH, et al: Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 3: 954-987, 2012.
16. Muntané J, De la Rosa AJ, Docobo F, Garcia-Carbonero R and Padillo FJ: Targeting tyrosine kinase receptors in hepatocellular carcinoma. Curr Cancer Drug Targets 13: 300-312, 2013.
17. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A and Montalto G: Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 3: 236-260, 2012.
18. Cai C, Teng L, Vu D, et al: The heme oxygenase 1 inducer (CoPP) protects human cardiac stem cells against apoptosis through activation of the extracellular signal-regulated kinase (ERK)/NRF2 signaling pathway and cytokine release. J Biol Chem 287: 33720-33732, 2012.
19. Xu X, Fan Z, Kang L, et al: Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest 123: 630-645, 2013.
20. Yang JY and Hung MC: Deciphering the role of forkhead transcription factors in cancer therapy. Curr Drug Targets 12: 1284-1290, 2011.
21. Arden KC: Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol 41: 709-717, 2006.
22. Hu MC, Lee DF, Xia W, et al: IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117: 225-237, 2004.
23. Potente M, Urbich C, Sasaki K, et al: Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 115: 2382-2392, 2005.
24. Brunet A, Bonni A, Zigmond MJ, et al: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999.
25. Yang JY, Zong CS, Xia W, et al: ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10: 138-148, 2008.
26. Kim SH, Jeong JH, Kim TI, Kim SW and Bull DA: VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine). Mol Pharm 6: 718-726, 2009.
27. Du J, Gao S, Luo J, et al: Effective inhibition of foot-and-mouth disease virus (FMDV) replication in vitro by vector-delivered microRNAs targeting the 3D gene. Virol J 8: 292, 2011.
28. Guerrero AD, Schmitz I, Chen M and Wang J: Promotion of caspase activation by caspase-9-mediated feedback amplification of mitochondrial damage. J Clin Cell Immunol 3: pii: 1000126, 2012.
29. Ranjan K, Surolia A and Pathak C: Apoptotic potential of Fas-associated death domain on regulation of cell death regulatory protein cFLIP and death receptor mediated apoptosis in HEK 293T cells. J Cell Commun Signal 6: 155-168, 2012.
30. Yamasaki Y, Yamasaki M, Tachibana H and Yamada K: Important role of β1-integrin in fucoidan-induced apoptosis via caspase-8 activation. Biosci Biotechnol Biochem 76: 1163-1168, 2012.
31. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N and Coombes KR: Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res 16: 1865-1874, 2010.
32. Vadlakonda L, Pasupuleti M and Pallu R: Role of PI3K-AKT-mTOR and Wnt signaling pathways in transition of G1-S phase of cell cycle in cancer cells. Front Oncol 3: 85, 2013.
33. Pardo PS, Lopez MA and Boriek AM: FOXO transcription factors are mechanosensitive and their regulation is altered with aging in the respiratory pump. Am J Physiol Cell Physiol 294: C1056-C1066, 2008.
34. Nho RS, Hergert P, Kahm J, Jessurun J and Henke C: Pathological alteration of FoxO3a activity promotes idiopathic pulmonary fibrosis fibroblast proliferation on type I collagen matrix. Am J Pathol 179: 2420-2430, 2011.
35. Wang X, Chen WR and Xing D: A pathway from JNK through decreased ERK and Akt activities for FOXO3a nuclear translocation in response to UV irradiation. J Cell Physiol 227: 1168-1178, 2012.
36. Xie C, Song LB, Wu JH, et al: Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a. PLoS One 7: e40607, 2012.
37. Ghosh AP, Klocke BJ, Ballestas ME and Roth KA: CHOP potentially co-operates with FOXO3a in neuronal cells to regulate PUMA and BIM expression in response to ER stress. PLoS One 7: e39586, 2012.
38. Zhao XC, Cao XC, Liu F, Quan MF, Ren KQ and Cao JG: Regulation of the FOXO3a/Bim signaling pathway by 5,7-dihydroxy-8-nitrochrysin in MDA-MB-453 breast cancer cells. Oncol Lett 5: 929-934, 2013.
39. Cunha DA, Igoillo-Esteve M, Gurzov EN, et al: Death protein 5 and p53-upregulated modulator of apoptosis mediate the endoplasmic reticulum stress-mitochondrial dialog triggering lipotoxic rodent and human β-cell apoptosis. Diabetes 61: 2763-2775, 2012.
40. He L, Yang X, Cao X, Liu F, Quan M and Cao J: Casticin induces growth suppression and cell cycle arrest through activation of FOXO3a in hepatocellular carcinoma. Oncol Rep 29: 103-108, 2013.
41. Chen Q, Ganapathy S, Singh KP, Shankar S and Srivastava RK: Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 5: e15288, 2010.
42. Boreddy SR, Pramanik KC and Srivastava SK: Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clin Cancer Res 17: 1784-1795, 2011.
43. Roy SK, Srivastava RK and Shankar S: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 5: 10, 2010.
44. Shankar S, Marsh L and Srivastava RK: EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin. Mol Cell Biochem 372: 83-94, 2013.
45. Srivastava RK, Unterman TG and Shankar S: FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Mol Cell Biochem 337: 201-212, 2010.